{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:19:18Z","timestamp":1778735958196,"version":"3.51.4"},"reference-count":89,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,11,21]],"date-time":"2008-11-21T00:00:00Z","timestamp":1227225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>While supportive care remains the best option for most well children with sickle cell disease (SCD), increasing awareness of early signs of chronic organ damage in childhood has focused attention on therapy which modulates the natural history of the disease. Since cure by stem cell transplantation is only feasible for a minority and gene therapy remains developmental, pharmacological modification by Haemoglobin F (HbF)\u2010inducers, is the most widely used approach in SCD. Currently, the only HbF modulator with a clear place in the management of childhood SCD is hydroxycarbamide for which the main indications are frequent painful crises and recurrent acute chest syndrome. In the majority of SCD children treated with hydroxycarbamide there is clear evidence of clinical benefit and the drug is well tolerated. The main disadvantages are the need for frequent monitoring and uncertainity about long\u2010term risks of carcinogenicity and impaired fertility, although these risks appear to be very low. The role of hydroxycarbamide in sickle\u2010associated central nervous system disease remains to be established. Decitabine and butyrate derivatives show some promise although robust data in children with SCD are lacking. A number of other drugs are currently under investigation for their effects on HbF production including thalidomide and lenolidamide.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07482.x","type":"journal-article","created":{"date-parts":[[2008,11,21]],"date-time":"2008-11-21T07:29:35Z","timestamp":1227252575000},"page":"308-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Haemoglobin F modulation in childhood sickle cell disease"],"prefix":"10.1111","volume":"144","author":[{"given":"Sara","family":"Trompeter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065201"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04144.x"},{"key":"e_1_2_6_4_1","first-page":"1790","article-title":"Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease","volume":"93","author":"Atweh G.F.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.67.4.517"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2113"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-005-1419-5"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-079665"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11515"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.2.643.643"},{"key":"e_1_2_6_11_1","first-page":"467","article-title":"Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease","volume":"137","author":"Chaine B.","year":"2001","journal-title":"Archives of Dermatology"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.15.4842"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06707.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.V21.3.261.261","article-title":"Hereditary persistance of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore","volume":"21","author":"Conley C.L.","year":"1963","journal-title":"Blood"},{"key":"e_1_2_6_16_1","article-title":"Hydroxyurea for sickle cell disease","author":"Davies S.","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_6_17_1","unstructured":"De Montalembert M.(2007)Hydroxyurea: Benefits and Risks in Patients Affected with Sickle Cell Anemia. Hematology Education 2007 Book 1 Education Program 12th EHA Annual Congress http:\/\/www.ehaweb.org\/education."},{"key":"e_1_2_6_18_1","first-page":"125","article-title":"Long\u2010term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes","volume":"91","author":"De Montalembert M.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.14.4428"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.3905"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.3.735.735"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199208203270818"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2006.01.002"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-076091"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3628"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3096"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20296"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-008318"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30920"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.11.4727-4741.2005"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2704"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03849.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4973"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21271"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06884.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880010802107273"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2008.02.003"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21104"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0687"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200303000-00015"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2006.07.001"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200421633"},{"key":"e_1_2_6_44_1","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG\u2010KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group","volume":"94","author":"Kinney T.R.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2379"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20819"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07045.x"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00113.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-12-200806170-00221"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21020"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-009506"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-102244"},{"key":"e_1_2_6_53_1","first-page":"1076","article-title":"Combination erythropoietin\u2010hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review","volume":"91","author":"Little J.A.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500433"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093948"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-3-50"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00182.x"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365510601046557"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2003.027326"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32322"},{"key":"e_1_2_6_61_1","volume-title":"Sickle Cell disease in Childhood \u2013 Standards and Guidelines for Clinical Care. Detailed Guidance","author":"NHS Sickle Cell and Thalassaemia Screening Programme","year":"2007"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.113471"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-88-1-1"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0708272"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406093302303"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.11.5039"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000189089.45003.52"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3758"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200212000-00011"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.189696"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11474"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.02.006"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000219658.57915.d4"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1738"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07027.x"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21480"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1263(200009\/10)20:5<407::AID-JAT704>3.0.CO;2-T"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10205"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10937"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402168"},{"key":"e_1_2_6_81_1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V83.4.1124.1124","article-title":"A cautionary note regarding hydroxyurea in sickle cell disease","volume":"83","author":"Vichinsky E.P.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.119590"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.121383"},{"key":"e_1_2_6_84_1","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood.V94.9.3022","article-title":"Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease","volume":"94","author":"Ware R.E.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.10"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-194804000-00008"},{"key":"e_1_2_6_87_1","first-page":"704","article-title":"Inherited haemoglobin disorders: an increasing global health problem","volume":"79","author":"Weatherall D.J.","year":"2001","journal-title":"Bulletin of the World Health Organisation"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0454"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2475"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-057893"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07482.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07482.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:47:08Z","timestamp":1695919628000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07482.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,16]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07482.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07482.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,16]]},"assertion":[{"value":"2009-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}